The RWD & RWE Podcast

19 October 2022: Nicole Bailey MPH – RWW: HELP WANTED in RWD/RWE: Growth is fueling new opportunities!

19 October 2022: Conversation with Nicole Bailey MPH Vice President Real-World Data at Aetion – We discussed the variety of career opportunities in the RWD/RWE industry

12 October 2022: Alexa Berk PhD, Elli Brimble MS – RWW: RWD-supported drug filing and regulatory approval

12 October 2022: Conversation with Alexa Berk PhD (Medical Affairs Director, Digital Health and Data Platforms) and Elli Brimble MS (Research Director, Rare DiseaseResearch Director, Rare Disease) at Invitae (formerly Ciitizen) – We discussed a recent drug approval based on RWE from a RWD-driven digital natural history study in rare disease: https://www.prnewswire.com/news-releases/invitaes-real-world-ciitizen-data-utilized-in-praxis-precision-medicines-prax-222-ind-filing-301627677.html

5 October 2022: Jeffrey Yu, MD – RWW: Discussion with imaging RWD pioneer Jeffrey Yu, MD

5 October 2022: Conversation with Jeffrey Yu MD, radiologist and founder of OneMedNet – We discussed Dr. Yu’s journey in the RWD arena and tremendous value of imaging data in the research ecosystem today

28 September 2022: Jen Cubino – RWW: Meeting the challenges of real-world data access

28 September 2022: Conversation with Jen Cubino MA, Chief Operating Officer at BC Platforms – We discussed maturing the global market for sharing large scale, RWD, ethically! This discussion will build on Jen's article: Meeting the challenges of real-world data access: https://www.mednous.com/system/files/2022-04/Real-world%20data%20Jennifer%20Cubino%20Apr%202022.pdf

21 September 2022: Michael Howley PA-C PhD and Peter Malamis MBA – RWW: Article review with Michael Howley and Peter Malamis

21 September 2022: Conversation with Michael Howley PA-C PhD and Peter Malamis MBA – We discussed the articles they have published on AppliedClinicalTrialsOnline.com: "The Limited Future of Real-World Data", "The Real-World Data That Matters", and "Current and Future Use of Real-World Data".

14 September 2022: Elise Berliner PhD – RWW: Patient registries in the era of accessible RWD

14 September 2022: Conversation with Elise Berliner PhD, Global Senior Principal of RWE Strategy at Cerner Enviza – We discussed on patient registries as sources of RWD. What are they, how are they set-up, what are their major benefits, differentiators, limitations, etc.

7 September 2022: Jason Martin MS MBA – RWE is perfect…in theory! Solving barriers to RWD adoption.

7 September 2022: Conversation with Jason Martin MS MBA, Managing Director & Founder of Global Outcomes LLC – We discussed characterizing & addressing the complexities of running rwd studies and why adoption has been slow.

31 August 2022: Sheila Mahoney MBA – Poster Review: ”RWE Thought Experiment: Could RWE Have Prevented Today’s Opioid Epidemic? Lessons from 19th Century China.”

31 August 2022: Conversation with Sheila Mahoney MBA, creator of LifeSciHub – We discussed LifeSciHub, an actionable Community of small independent workforce businesses in Life Sciences R&D; and we then discussed her poster presented at DIA 2022, found at: https://www.eposters.net/poster/rwe-thought-experiment-could-rwe-have-prevented-todays-opioid-epidemic-lessons-from-19th-century: "RWE Thought Experiment: Could RWE Have Prevented Today's Opioid Epidemic? Lessons from 19th Century China."

24 August 2022: John Cai, MD, PhD, FAMIA – RWW: Article review: ”RWD/RWE: To Replicate Or Continue To Learn In The Real World?”

24 August 2022: Conversation with John Cai, MD, PhD, FAMIA, Executive Director, Real-world Data Analytics and Innovation at Merck – We discussed the article published on ClinicalLeader.com: "RWD/RWE: To Replicate Or Continue To Learn In The Real World?" (https://www.clinicalleader.com/doc/rwd-rwe-to-replicate-or-continue-to-learn-in-the-real-world-0001).

10 August 2022: Viraj Narayanan – RWW: RWD without SDoH - a complete view of the patient?

10 August 2022: Conversation with Viraj Narayanan, MBA, Chief Commercial Officer at Ontada – We discussed: How do we close the gap between patients who could benefit from a therapy and what happens in the real world? How can we ensure that patients that could benefit from a therapy are enrolled in respective clinical trials or receive the appropriate therapy post-approval? How can we build representative RWE for these populations, while understanding social determinants of health that may influence patient’s accessibility and availability for clinical research and long-term follow up?